Dougherty Initiates Coverage on Phase Forward (PFWD) with a Buy
More News related to PFWD
- Phase Forward Named Private Sector Company of the Year by Mass Technology Leadership Council
- Phase Forward Signs Multi-Year Agreement with Quotient Clinical for Use of InForm(TM) Electronic Data Capture Solution
- Phase Forward (PFWD) Announces $40M Share Buyback
- Phase Forward Announces Share Repurchase Program
- Phase Forward to Present at the 18th Annual Credit Suisse Healthcare Conference
More News related to New Coverage
- Sidoti & Co Initiates Coverage on Stratasys (SSYS) with a Neutral
- ThinkEquity Initiates Coverage on Sourcefire (FIRE) with a Buy
- Raymond James Initiates Coverage on Knight Capital (NITE) with a Market Perform
- Raymond James Initiates Coverage on International Game Technology (IGT) with a Market Perform
- Thomas Weisel Initiates Coverage on UQM Technologies (UQM) with an Overweight
Dougherty initiates coverage on Phase Forward (Nasdaq: PFWD) with a Buy. Price target $22.50.
Phase Forward Incorporated is a provider of integrated enterprise-level software products, services and hosted solutions for use in the global clinical trial and drug safety monitoring activities of its customers.
Related Categories
New CoverageStocks Mentioned
-0.33Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
